Browsing by Author "Naidoo, Kalendri."

Now showing 1 - 3 of 3

Evaluation of haematological parameters and immune markers in HIV-infected and non-infected pre-eclamptic Black women.
(2007) Naidoo, Kalendri.; Moodley, Jagidesa.
This study focuses on women with both pre-eclampsia and Human Immunodeficiency Virus (HIV). Pre-eclampsia is a pregnancy-specific syndrome that occurs after 20 weeks gestation. Thrombocytopenia is the most common haematological abnormality in pre-eclampsia. Further, studies suggest that the immunological mechanism plays some role in the aetiology of pre-eclampsia. The immunological hallmark of HIV infection is a progressive decline in the number of CD4 T lymphocytes and significant haematological abnormalities are also common in HIV-infected individuals i.e. anaemia, thrombocytopenia and leukopenia. The study population comprised of two groups i.e., pre-eclamptic HIV-positive African women and preeclamptic HIV-negative African women as the control group. Samples were analysed for haematological parameters (full blood count) and immunological markers (flow cytometry). There was no statistical significance in the following parameters: RBC, Hb, haematocrit, MCV, MCH, MCHC, platelets, MPV, WBC, lymphocytes, neutrophils, eosinophils, monocytes, basophils and CD8. There was a statistical difference in the CD3 and CD4 counts between both the groups. However, the CD3 and CD4 counts were within the normal range in the HIV-negative pre-eclamptic group and even though CD3 decreased, it was still within the normal range in the HIV-positive pre-eclamptic group, with CD4 decreasing below the normal range in the HIV-positive pre-eclamptic group. This suggests that immune mechanisms involving CD estimations do not play a role in pre-eclampsia since the decrease in the counts can be solely attributed to HIV infection. Results obtained in this study do not show any severe haematological or immunological abnormalities when women have both pre-eclampsia and HIV infection.
Immune evaluation of HIV-infected and noninfected pre-eclamptics.
(MedPharm, 2009) Naidoo, Kalendri.; Pupuma, Xanti Bongo S.; Moodley, Jagidesa.
No abstract available.
Narratives from women using the dapivirine vaginal ring in an open label extension study by Kalendri Naidoo.
(2022) Naidoo, Kalendri.; Mansoor, Leila Essop.; Montgomery, Elizabeth T.
In sub-Saharan Africa, women and girls represented 63% of new Human Immunodeficiency Virus (HIV) infections in 2020. Adolescent girls and young women (AGYW) aged 15–24 years are twice as likely to be living with HIV as compared to young men. Therefore, efforts to develop and roll out safe, effective and acceptable HIV prevention products for women, are continuing. An important example of a female-initiated HIV prevention strategy is the dapivirine vaginal ring which showed a 27% reduction in HIV-1 incidence in the Microbicides Trials Network (MTN)-020/A Study to Prevent Infection with a Ring for Extended Use (ASPIRE) study and by 31% in the International Partnership for Microbicides (IPM)-027 The Ring study. The dapivirine vaginal ring was subsequently tested for safety and adherence in the Open Label Extension (OLE), MTN-025/HIV Open-label Prevention Extension (HOPE) study. The MTN-032/Adherence in HOPE and ASPIRE (AHA) study was a two-phase exploratory sub-study of the ASPIRE (AHA part 1, after ASPIRE and before HOPE study initiation) and HOPE (AHA part 2, after HOPE was completed) studies which utilised single qualitative indepth interviews (IDIs) to explore social conditions and issues related to participation around the use of the dapivirine vaginal ring as well as suitable approaches to market the study product. I report on the narratives from women participating in the AHA study (Part 2) within the context of known safety, partial product efficacy and choice, focusing on what motivated women to join the HOPE OLE study, women’s understanding of the vaginal rings’ efficacy, how they understood it to work in their bodies to prevent HIV and barriers and motivators to vaginal ring adherence.